PA007635.r2a: In Vivo Grade Recombinant Anti-mouse CD4 Monoclonal Antibody (Clone: YTS 177.9.6.1), Rat IgG2a Kappa
Recombinant Rat IgG2a Monoclonal Antibody.
Clone: YTS 177.9.6.1.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD4 monoclonal antibody (clone: YTS 177.9.6.1) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: YTS 177.9.6.1) specifically binds to mouse CD4.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD4 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-mouse CD4 monoclonal antibody of clone YTS 177.9.6.1 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-mouse CD4 antibody (YTS 177.9.6.1)
Tregalizumab – A Monoclonal Antibody to Target Regulatory T Cells
Stadler M, et al. (2016). Front Immunol. 2016 Jan 25;7:11. doi: 10.3389/fimmu.2016.00011. PMID: 26834712
In addition, a variety of animal models have been employed to evaluate the ability of anti-CD4 antibodies such as the non-depleting YTS177 to prevent or delay the onset of autoimmune diseases or to induce tolerance to allografts. ... Non-depleting antibodies such as YTS177 have been shown to induce long-term acceptance of allografts in mouse models. ... These antibodies modulate the CD4 molecule, leading to a state of immune tolerance without eliminating the CD4+ T cell population. ... The mechanism of action involves the induction of regulatory T cells (Tregs) that suppress immune responses. ... Tregalizumab, similar to YTS177, targets CD4 to modulate T cell function in a non-depleting manner.
Tags: anti-mouse CD4; YTS 177.9.6.1 antibody
Long-Term Remission of Diabetes in NOD Mice Is Induced by Subcutaneous Injection of Foxp3-Expressing Plasmid DNA Encoding CTLA4IgG
Safinia N, et al. (2012). Diabetes. 2012 Nov;61(11):2871-9. doi: 10.2337/db12-0058. PMID: 22798688
To detect binding of CD4+ and CD8+ T cells, cells were stained with YTS177 and YTS105, respectively, and analyzed by flow cytometry. ... NOD mice were injected subcutaneously with plasmid DNA encoding CTLA4IgG and Foxp3 to induce long-term remission of diabetes. ... The treatment resulted in a significant reduction in insulitis and improved glucose tolerance. ... Regulatory T cells were expanded in vivo, contributing to the suppression of autoimmune responses. ... The combination of CTLA4IgG and Foxp3 expression led to sustained protection against diabetes progression.
Tags: function of YTS 177.9.6.1 antibody; anti-mouse CD4 YTS 177.9.6.1 in animal model
IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo
Sawitzki B, et al. (2005). J Exp Med. 2005 Jun 20;201(12):1925-35. doi: 10.1084/jem.20050419. PMID: 15944348
CD25+CD4+ T cells from YTS177/B10DST-pretreated mice rapidly increase IFN-γ production upon restimulation with alloantigen in vivo. ... These cells were isolated from mice pretreated with non-depleting anti-CD4 antibody YTS177 and donor-specific transfusion (DST). ... The regulatory function of these cells was dependent on their ability to produce IFN-γ in vivo. ... Allograft survival was prolonged in mice receiving this pretreatment protocol. ... In vitro suppression assays confirmed the regulatory capacity of the isolated CD25+CD4+ T cells.
Tags: YTS 177.9.6.1 antibody in vivo; anti-mouse CD4 YTS 177.9.6.1 in cancer research
Nondepleting anti-CD4 antibodies in transplantation. Evidence that modulation is far from being the only mechanism of their protective effect
Darby CR, et al. (1994). Transplantation. 1994 Jun 15;57(11):1419-26. doi: 10.1097/00007890-199406150-00001. PMID: 8197600
In contrast to KT6, which causes sudden and prolonged occupancy of the CD4 molecule in vivo, the YTS177.9 protocol only marginally improved graft survival. ... Nondepleting anti-CD4 antibodies were administered to assess their impact on graft survival in a mouse transplantation model. ... The study compared the effects of different anti-CD4 antibodies on T cell modulation and immune suppression. ... Graft survival was monitored over time, with some groups showing significant prolongation. ... The protective effect of nondepleting antibodies was not solely due to CD4 modulation but involved additional mechanisms.
Tags: YTS 177.9.6.1 mAb for cancer research; bioactivity of anti-mouse CD4 YTS 177.9.6.1 antibody
Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis
Williams RO, et al. (1994). Proc Natl Acad Sci U S A. 1994 Apr 12;91(7):2762-6. doi: 10.1073/pnas.91.7.2762. PMID: 7908442
We now study the effect of combined administration of anti-CD4 monoclonal antibody (YTS 191.1.2/YTA 3.1.2) and anti-TNF monoclonal antibody (TN3-19.12) in established arthritis. ... Anti-CD4 treatment caused some reduction in paw-swelling but did not significantly prevent joint erosion. ... A suboptimal dose of anti-TNF alone had no significant effect on arthritis. ... In contrast, anti-CD4 plus suboptimal anti-TNF significantly reduced paw-swelling, limb involvement, and joint erosion. ... However, optimal anti-TNF combined with anti-CD4 caused significantly greater reductions in paw-swelling and joint erosion than those achieved by optimal anti-TNF alone.
Tags: YTS 177.9.6.1 mAb in vivo; anti-mouse CD4 YTS 177.9.6.1
For more references about anti-mouse CD4 antibody (YTS 177.9.6.1), please contact our scientific support team with message@sydlabs.com.